Ontology highlight
ABSTRACT: Introduction
Recently, accurate machine learning and deep learning approaches have been dedicated to the investigation of breast cancer invasive disease events (IDEs), such as recurrence, contralateral and second cancers. However, such approaches are poorly interpretable.Methods
Thus, we designed an Explainable Artificial Intelligence (XAI) framework to investigate IDEs within a cohort of 486 breast cancer patients enrolled at IRCCS Istituto Tumori "Giovanni Paolo II" in Bari, Italy. Using Shapley values, we determined the IDE driving features according to two periods, often adopted in clinical practice, of 5 and 10 years from the first tumor diagnosis.Results
Age, tumor diameter, surgery type, and multiplicity are predominant within the 5-year frame, while therapy-related features, including hormone, chemotherapy schemes and lymphovascular invasion, dominate the 10-year IDE prediction. Estrogen Receptor (ER), proliferation marker Ki67 and metastatic lymph nodes affect both frames.Discussion
Thus, our framework aims at shortening the distance between AI and clinical practice.
SUBMITTER: Massafra R
PROVIDER: S-EPMC9932275 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Massafra Raffaella R Fanizzi Annarita A Amoroso Nicola N Bove Samantha S Comes Maria Colomba MC Pomarico Domenico D Didonna Vittorio V Diotaiuti Sergio S Galati Luisa L Giotta Francesco F La Forgia Daniele D Latorre Agnese A Lombardi Angela A Nardone Annalisa A Pastena Maria Irene MI Ressa Cosmo Maurizio CM Rinaldi Lucia L Tamborra Pasquale P Zito Alfredo A Paradiso Angelo Virgilio AV Bellotti Roberto R Lorusso Vito V
Frontiers in medicine 20230202
<h4>Introduction</h4>Recently, accurate machine learning and deep learning approaches have been dedicated to the investigation of breast cancer invasive disease events (IDEs), such as recurrence, contralateral and second cancers. However, such approaches are poorly interpretable.<h4>Methods</h4>Thus, we designed an Explainable Artificial Intelligence (XAI) framework to investigate IDEs within a cohort of 486 breast cancer patients enrolled at IRCCS Istituto Tumori "Giovanni Paolo II" in Bari, It ...[more]